INFINITY PHARMACEUTICALS INC's ticker is INFI and the CUSIP is 45665G303. A total of 74 filers reported holding INFINITY PHARMACEUTICALS INC in Q2 2017. The put-call ratio across all filers is 0.76 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $445,000 | +49.3% | 219,652 | -2.3% | 0.03% | +65.0% |
| Q3 2017 | $298,000 | -17.9% | 224,793 | -2.8% | 0.02% | -23.1% |
| Q2 2017 | $363,000 | -58.4% | 231,293 | -14.5% | 0.03% | -57.4% |
| Q1 2017 | $873,000 | +139.2% | 270,417 | -0.1% | 0.06% | +144.0% |
| Q4 2016 | $365,000 | -31.4% | 270,749 | -20.6% | 0.02% | -34.2% |
| Q3 2016 | $532,000 | +15.9% | 341,090 | -1.3% | 0.04% | +18.8% |
| Q2 2016 | $459,000 | -75.2% | 345,446 | -1.8% | 0.03% | -74.2% |
| Q1 2016 | $1,853,000 | +30.8% | 351,789 | +94.8% | 0.12% | +21.6% |
| Q4 2015 | $1,417,000 | -64.2% | 180,609 | -61.5% | 0.10% | -63.7% |
| Q3 2015 | $3,963,000 | +556.1% | 469,045 | +749.3% | 0.28% | +524.4% |
| Q2 2015 | $604,000 | -90.6% | 55,224 | -88.0% | 0.04% | -89.9% |
| Q1 2015 | $6,457,000 | -17.2% | 461,902 | 0.0% | 0.44% | -14.1% |
| Q4 2014 | $7,801,000 | +24.4% | 461,902 | -1.2% | 0.52% | +27.3% |
| Q3 2014 | $6,273,000 | – | 467,491 | – | 0.41% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 1,100,000 | $14,762,000 | 6.34% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,882,805 | $52,107,000 | 1.90% |
| Cheyne Capital Management (UK) LLP | 326,821 | $4,388,000 | 1.56% |
| BB BIOTECH AG | 2,320,737 | $31,144,000 | 1.27% |
| Broadfin Capital, LLC | 854,384 | $11,466,000 | 1.20% |
| HealthCor Management, L.P. | 1,162,200 | $15,597,000 | 0.80% |
| Orbimed Advisors | 4,736,900 | $63,569,000 | 0.66% |
| Rhenman & Partners Asset Management AB | 148,000 | $1,986,000 | 0.58% |
| SOUND ENERGY PARTNERS, INC. | 51,000 | $684,000 | 0.53% |
| Rock Springs Capital Management LP | 210,000 | $2,818,000 | 0.44% |